Five things for pharma marketers to know: Tuesday, April 18, 2017

1. Novartis has received a Breakthrough Therapy designation for its CAR-T therapy. The drugmaker has also embarked on a collaboration with Allergan to pair two experimental drugs in a mid-stage clinical trial for the treatment of nonalcoholic steatohepatitis, or NASH. (Reuters)

2. Kim Kardashian West's recent Instagram post about Diclegis, Duchesnay USA's morning-sickness drug, isn't part of a previous agreement with the FDA. The agency in 2015 required Kardashian West to republish an Instagram post, this time including full risk information, after sending a warning letter to the company. “Duchesnay USA is proud to continue working with Kim Kardashian West to help generate awareness and educate women about morning sickness,” a Duchesnay spokesperson said.

3. The most recent user-fee deal would likely benefit healthcare companies because it would provide the FDA approval process with more certainty and efficiency. (Modern Healthcare)

4. A lack of adherence to medications can explain why so many patients don't get better, have relapses, or sometimes die. For example, one-third of kidney transplant patients don't take their anti-rejection medications. (NYT)

5. UnitedHealth Group said revenue for Optum, its PBM and healthcare data and analytics business, rose 7.9%, to $21.2 billion, in the first quarter of 2017. (Reuters)